Q4 and Full Year 2017 I recently bought into GenMark about a month ago and they recently release their Q4 and Year End results. Here's some of the highlights and press release below.
Highlights
- Revenues for the fourth quarter of 2017 were $16.0 million, an increase of 8% over the prior year period
- Revenues for the full year 2017 were $52.5 million, representing an increase of 7% over 2016
- Placed 49 ePlex® analyzers in the fourth quarter of 2017
- Exited the year with an installed base of 196 ePlex analyzers in U.S. and European labs
- XT-8 installed base remained relatively stable at 620 analyzers in U.S. labs
“In 2017, we achieved several significant product launches that are fundamental to the continued growth and success of our business. We launched our FDA cleared ePlex system and Respiratory Pathogen Panel in the U.S. ahead of the current severe flu season, and we introduced our ePlex family of CE Marked BCID sepsis panels in Europe. We’re also very pleased with the recent launch of our ePlex NP system, which we designed to address lower test-volume sites and decentralized near patient settings,” said Hany Massarany, President and Chief Executive Officer. “Looking ahead, we are excited about the opportunity we have in 2018 and beyond, to drive ePlex commercialization with an expanded menu of test panels and a rapidly growing number of customers utilizing ePlex for routine clinical testing,” concluded Massarany.
https://globenewswire.com/news-release/2018/02/27/1396429/0/en/GenMark-Diagnostics-Reports-Fourth-Quarter-and-Full-Year-2017-Results.html